MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
OCGN stock logo

OCGN

Ocugen, Inc.

$1.79
0
 (0%)
Exchange:  NASDAQ
Market Cap:  586.936M
Shares Outstanding:  112.236M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Shankar Musunuri
Full Time Employees:  95
Address: 
263 Great Valley Parkway
Malvern
PA
19355
US
Website:  https://www.ocugen.com
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/09 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue6,0364,0554,413
Gross Profit5,3322,0872,024
EBITDA-64,827-52,789-60,527
Operating Income-65,531-54,757-62,916
Net Income-63,078-54,054-67,846

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets64,54782,44243,516
Total Liabilities23,98352,81056,455
Total Stockholders Equity40,56429,632-12,166
Total Debt6,94132,50333,144
Cash and Cash Equivalents39,46258,51418,571

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-62,054-42,142-56,964
Capital Expenditure-10,476-3,385-185
Free Cash Flow-72,530-45,527-57,149
Net Income-63,078-54,054-67,846
Net Change in Cash-38,10119,359-39,934

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)447,389.917Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)2,356,253.567Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,169,605Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-1,413,752.140Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-268,433.950Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-701,763Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)106,139.401Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)1,247,711.285Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)538,051.122Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)2,984,925.326Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)15,720,606.747Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)7,803,447.180Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.790Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)4.160Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.350Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)3Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
4.055M  ?P/S
 (TTM)
: 
147.86
?Net Income
 (TTM)
: 
-54054000  ?P/E
 (TTM)
: 
-9.16
?Enterprise Value
 (TTM)
: 
667.088M  ?EV/FCF
 (TTM)
: 
-11.67
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-26.26  ?ROIC
 (TTM)
: 
-2.69
?Net Debt
 (TTM)
: 
-26011000  ?Debt/Equity
 (TTM)
: 
-2.72
?P/B
 (TTM)
: 
-51.09  ?Current Ratio
 (TTM)
: 
1.06

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate OCGN Intrinsic Value

Common questions about OCGN valuation

Is Ocugen, Inc. (OCGN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Ocugen, Inc. (OCGN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is OCGN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OCGN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is OCGN’s P/E ratio?

You can see OCGN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for OCGN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is OCGN a good long-term investment?

Whether OCGN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

OCGN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0
MARKETSnap

Trading Metrics:

Open: 1.76   Previous Close: 1.79
Day Low: 1.72   Day High: 1.81
Year Low: 0.57   Year High: 2.73
Price Avg 50: 1.76   Price Avg 200: 1.4
Volume: 4.988M   Average Volume: 7.743M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy
22-04-2026 13:36
OCGN's Gene-Agnostic Strategy Could Reset Retinal Therapy
Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk
22-04-2026 13:36
Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
22-04-2026 13:36
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?
03-04-2026 12:31
Ocugen (OCGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
25-03-2026 13:15
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
20-03-2026 09:01
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read